SynthesisMedicine2018
Aldehyde dehydrogenase 1 as a predictor of the neoadjuvant chemotherapy response in breast cancer: A meta-analysis.
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Biomarkers of tumor invasiveness in proteomics (Review).International journal of oncology · 2020Pooled it
- Profiling of Breast Cancer Stem Cell Types/States Shows the Role of CD44International journal of molecular sciences · 2025Article
- ALDH1A1 in breast cancer: A prospective target to overcome therapy resistance (Review).Oncology letters · 2025Review
- Integrated single-cell and bulk RNA sequencing analysis identifies a neoadjuvant chemotherapy-related gene signature for predicting survival and therapy in breast cancer.BMC medical genomics · 2023Article
- The Concept of Cancer Stem Cells: Elaborating on ALDH1B1 as an Emerging Marker of Cancer Progression.Life (Basel, Switzerland) · 2023Review
- Article
- Drug-Tolerant Persister Cells in Cancer Therapy Resistance.Cancer research · 2022Review
- Transcriptional Expressions of ALDH1A1/B1 as Independent Indicators for the Survival of Thyroid Cancer Patients.Frontiers in oncology · 2022Article
- FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer.Cancer cell international · 2020Article
- The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer.Molecular and cellular biology · 2020Article
- L-Lactate dehydrogenase B may be a predictive marker for sensitivity to anti-EGFR monoclonal antibodies in colorectal cancer cell lines.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany reports suggest that aldehyde dehydrogenase 1 (ALDH1) expression is associated with poorer neoadjuvant chemotherapy (NAC) response in patients with breast cancer; however, the prognostic value of this enzyme in cancer has yet to be confirmed. Therefore, we conducted a meta-analysis of related studies to investigate the relationship between ALDH1 expression and the NAC response in breast cancer patients.
methodsPubMed, Web of Science, ScienceDirect, Cochrane Library, and EMBASE were searched for potentially eligible literature. The study characteristics and relevant data were extracted. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled to estimate the prognostic role of ALDH1 in the NAC response in patients with breast cancer. The robustness of our results was confirmed by sensitivity and publication bias analyses.
resultsPooled meta-analysis of 10 eligible studies including 1081 patients indicated an association between high ALDH1 expression and poor NAC responses (pooled OR = 0.44, 95% CI: 0.25-0.77, P = .004) with low significant heterogeneity (I = 55.1%, P = .018). During subgroup analyses, we found that the recipient sample size presents a potential source of heterogeneity. Begg funnel plot and Egger test showed no possible publication bias. Sensitivity analysis suggested that the pooled OR was robust.
conclusionOur results suggested that higher ALDH1 expression is associated with poorer NAC responses in patients with breast cancer. However, given the limited number of studies analyzed in this work, more studies are necessary to verify our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.